<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g65" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-56.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-47.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-56.html" >Diseases Characterized by Genital, Anal, or Perianal Ulcers</a><span class="carrot"> > </span>
                    <a href="lv-56.html" >Genital HSV Infections</a><span class="carrot"> > </span>Severe Disease
            </div>
            </br><h3 class="sgc-1" id="sigil_toc_id_65">
 Severe Disease
</h3>
<p>
 Intravenous (IV) acyclovir therapy should be provided for patients who have severe HSV disease or complications that necessitate hospitalization (e.g., disseminated infection, pneumonitis, or hepatitis) or CNS complications (e.g., meningoencephalitis). The recommended regimen is acyclovir 5&ndash;10 mg/ kg IV every 8 hours for 2&ndash;7 days or until clinical improvement is observed, followed by oral antiviral therapy to complete at least 10 days of total therapy. Acyclovir dose adjustment is recommended for impaired renal function.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

